

The 7th International Electronic Conference on Medicinal Chemistry (ECMC 2021) 01–30 NOVEMBER 2021 | ONLINE

Chitosan-based biocomposites as H₂S vehicles

Mary Batista¹, Moisés L. Pinto², Fernando Antunes², João Pires^{2*}, and Silvia Carvalho^{1,2*}


 ¹ Centro de Química Estrutural, Faculdade de Ciências da Universidade de Lisboa, 1749-016, Lisboa, Portugal;
² CERENA, Departamento de Engenharia Química, Instituto Superior Técnico, Universidade de Lisboa, 1049-001, Lisboa, Portugal.

• Corresponding authors: silvia.carvalho@tecnico.ulisboa.pt and jpsilva@fc.ul.pt





Chitosan-based biocomposites as H₂S vehicles





Abstract

Hydrogen sulphide (H_2S) is commonly known due to its toxicity, and rotten egg smell, yet the detection of endogenously produced H_2S in the brain tissues of mammals in 1989 changed the ways scientists looked at this gas. Currently, H_2S is a gasotransmitter (small gaseous molecules involved in signalling processes) and its exogenous delivery has many potential therapeutic applications (*e.g.*, wound healing, cardiovascular diseases). The therapeutical use of H_2S is challenging, being crucial maintaining its level in the body within the therapeutic window, at the risk of having toxic effects.

In this work, we synthesised chitosan biocomposites using porous materials (type A zeolites and an activated carbon obtained from glycerine) and conducted studies to evaluate the possibility of being used as H_2S vehicles. The biocomposites were characterised and their H_2S adsorption capacity and release profile in aqueous solution at pH 7 were evaluated by volumetric method and Ellman's reagent, respectively. Cytotoxicity assays using HeLa cells for all chitosan biocomposites were performed, as well as for the H_2S loaded material that showed the most promising aqueous solution release results.

Keywords: biocomposites; chitosan; H₂S vehicles




Introduction




- H₂S is commonly known by its rotten-egg smell and high toxicity;
- However, it is a gasotransmitter and it may have therapeutic applications;
- This application is limited due to delivery problems.

Porous materials




- Porous materials are solid containing void space;
- Their high surface area led to a high gas payload;
- In recent years, they have been investigated as potential drug vehicles;
- Biocompatibility issues may be overlapped by surface modification with biocompatible polymers.






In this work:





Results and discussion

Synthesis




Activated carbon biocomposite

Zeolite (3A, 4A and 5A) biocomposites




Characterisation - FTIR

Activated carbon materials






Characterisation - TG-DSC



Sample	Parent material		Material with Chitosan		Chitosan (%)
	225 °C	525 °C	225 °C	525 °C	
3A	16.5	20.7	16.9	26.1	5.4
4A	17	21.6	17.9	28.4	10.5
5A	17.3	22.7	19.8	28.9	9.1
Gta@600	9.1	53.1	8.3	75.6	23.3




Characterisation - XRD and SEM






Characterisation - N₂ isotherms






H₂S Adsorption





H₂S release in aqueous solution at pH 7






Cytotoxicity studies

HeLa viability in the presence of unloaded materials (450 μ g/mL).

Each bar represents an average (of 3 independent experiments each one with 8 replicates) \pm SD.

HeLa viability in the presence of H_2S loaded material (5A@Chi - 0.5 mg/mL and 2.0 mg/mL). Each bar represents an average (of 3 independent experiments each one with 2 replicates) \pm SD.





Conclusions

- The modification of the materials with chitosan was successfully achieved;
- The 5A zeolite showed the higher adsorption capacity for H₂S;
- The H₂S release studies in aqueous solutions showed that the composite 5A@Chi had the longest release time (120 min);
- Cytotoxicity studies showed all the materials are no toxic to HeLa cells;
- H₂S loaded 5A@Chi also showed no cytotoxicity to HeLa cells;
- 5A@Chi are the most promising material for further studies.



Acknowledgments

This research was financed by Fundação para a Ciência e a Tecnologia (FCT) through projects PTDC/MEDQUI/28721/2017 and developed in the scope of the projects UIDB/00100/2020 (CQE), UIDB/04028/2020 & UIDP/04028/2020 (CERENA), financed by Portuguese funds through the FCT/MEC and when applicable co-financed by FEDER under the PT2020 Partnership Agreement.

Mary Batista acknowledges for FCT-Investigator contract-DL57.





